Abstract
CGP 9000 (cefroxadine), a new cephalosporine derived from N-acyl-3-alkoxy-7-amino-3-cefem-4-carboxylic acid for exclusively oral use, has been experimented on 67 patients, 41 adults and 20 children. CGP 9000 appeared to possess good therapeutic activity, even in low doses: its rapid absorption and moderate sero-protein bond are a guarantee of an immediate and almost total bioavailability.
MeSH terms
-
Adolescent
-
Adult
-
Bacterial Infections / drug therapy*
-
Biological Availability
-
Bronchitis / drug therapy
-
Bronchopneumonia / drug therapy
-
Cephalosporins / therapeutic use*
-
Cephradine / analogs & derivatives
-
Cephradine / therapeutic use*
-
Child
-
Child, Preschool
-
Cystitis / drug therapy
-
Drug Evaluation
-
Erysipelas / drug therapy
-
Female
-
Humans
-
Infant
-
Male
-
Middle Aged
-
Mouth Diseases / drug therapy
-
Parotitis / drug therapy
-
Scarlet Fever / drug therapy
Substances
-
Cephalosporins
-
cefroxadine
-
Cephradine